The leukemic stem cell

Best Practice and Research in Clinical Haematology

Volumn 20, Issue 1, 2007, Pages 13-18

  Jordan, Craig T ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

leukemic stem cell; parthenolide; TDZD 8

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HEAT SHOCK PROTEIN INHIBITOR; HISTONE DEACETYLASE INHIBITOR; I KAPPA B; IDARUBICIN; NUCLEOSIDE ANALOG; PARTHENOLIDE; PLACEBO; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER STEM CELL; CELL POPULATION; CELL SPECIFICITY; CELL TYPE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA; SESQUITERPENES; THIADIAZOLES; TUMOR STEM CELLS;

EID: 33847229041     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.10.005     Document Type: Review

References (11)

1. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 3 (1997) 730-737
2. Gilliland D.G., Jordan C.T., and Felix C.A. The molecular basis of leukemia. Hematology/The Education Program of the American Society of Hematology (2004) 80-97
3. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
4. Tallman M.S. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology/The Education Program of the American Society of Hematology (2005) 143-150
5. Kantarjian H.M., Estey E.H., and Keating M.A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10 supplement 1 (1996) S4-S6
6. Li T.K., Houghton P.J., Desai S.D., et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Research 63 (2003) 8400-8407
7. Deininger M.W., and Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacological Reviews 55 (2003) 401-423
8. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
9. Xu Q., Simpson S.E., Scialla T.J., et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
10. Guzman M.L., Swiderski C.F., Howard D.S., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences of the USA 99 (2002) 16220-16225
11. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105 (2005) 4163-4169